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A BCS-based biowaiver allows extrapolation of drug product bioequivalence (when 23 
applicable) based on the BCS class of the drug and in vitro dissolution testing. Drug 24 
permeability and solubility considerations for adult BCS might not apply directly to paediatric 25 
subpopulations and bridging of adult and paediatric formulations should be undertaken with 26 
caution.  27 
The aims of this study were to: (i.) identify compounds which would change drug solubility 28 
classification in the paediatric population, and (ii.) to assess the risk of extending BCS-based 29 
biowaiver criteria into paediatric products of these compounds. Amoxicillin, prednisolone, and 30 
amlodipine were selected as the model compounds.  31 
Dissolution studies of IR formulations of these compounds were conducted with USP II 32 
(paddle) and mini-paddle apparatus, in media of three pHs (pH 1.2, 4.5 and 6.8). Three 33 
dissolution setups were tested: (1) ‘typical’ BCS-based biowaiver conditions, (2) “BE” setup 34 
derived from BE study protocols (volume: 250 mL), and (3) “paediatric” setup based on 35 
representative volume for the paediatric population (50 mL). 36 
Results revealed that extension of regulated BCS-based biowaiver criteria for paediatric 37 
application is not as simple as scaling down volumes. It was further shown that BCS-based 38 
biowaiver criteria should not be applied when there is the risk of change of the drug solubility 39 
class, from the adult to paediatric populations. 40 
A deeper knowledge of the paediatric gastrointestinal environment is still lacking and would 41 
assist in refining the biopharmaceutical tools needed to appropriately evaluate formulation 42 
performance across age groups. This would potentially reduce the number of clinical studies 43 
required and speed up formulation development.  44 
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Abbreviations 48 
AUC: area under the curve 49 
BA: bioavailability 50 
BCS: biopharmaceutics classification system 51 
BE: bioequivalence 52 
Cmax: maximum plasma concentration 53 
EMA: European Medicines Agency 54 
FDA: Food and Drug Administration 55 
GI: gastrointestinal 56 
ICH: International Council for Harmonisation of Technical Requirements for Pharmaceuticals 57 
for Human Use 58 
IR: immediate release 59 
WHO: World Health Organization 60 
PK: pharmacokinetic  61 
RC: regenerated cellulose 62 
RPM: revolutions per minute 63 
ST: standard deviation 64 
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Tmax: time to maximum concentration 65 
USP: United States Pharmacopeia 66 
USP NF: United States Pharmacopeia and National Formulary 67 
V0: initial gastric volume available  68 
5 
 
1. Introduction 69 
Biopharmaceutical tools are extensively used in the design and development of pharmaceutical 70 
formulations, namely in risk assessment and optimisation of formulation performance. The 71 
application of these tools in paediatric medicines is currently still limited (Batchelor et al., 72 
2013). Despite the increased effort put into improving the safety and effectiveness of paediatric 73 
medicines, development of medicines for this population is hindered by ethical considerations 74 
and technical constraints (e.g. physiological and anatomical changes), leading to knowledge 75 
gaps (Batchelor, 2014; Daousani and Karalis, 2017; Elder et al., 2017; Giacoia et al., 2012). 76 
Consequently, the tools currently used to undertake biopharmaceutical risk assessment of 77 
paediatric formulations are based on adult tests, addressing adult physiology and anatomy 78 
(Batchelor et al., 2013). However, the paediatric population has distinct needs with respect to 79 
formulation design and performance and thus adult formulations may not be suitable. Due to 80 
the challenges faced during paediatric medicine development, regulations have been reformed 81 
to address paediatric drug development in parallel to adult formulations (Daousani and Karalis, 82 
2017; Elder et al., 2017). Preliminary enabling formulations, i.e. drug delivery technologies 83 
specially designed to expedite the release and subsequently absorption of drugs, might be used 84 
in early paediatric studies, followed by a confirmatory study in which better-designed market 85 
formulations are introduced (Ricci, 2013). Supportive clinical studies (e.g. relative BA or BE 86 
in adults) or in vitro techniques may then be used to establish the bridge from adult and/or 87 
enabling formulations to the final paediatric formulation.  88 
From a regulatory perspective, during drug development a BE study should be conducted for a 89 
new formulation that has not been tested in pivotal efficacy trials. PK parameters of two 90 
formulations (i.e. AUC, Cmax and Tmax) are compared; if the rate and extent of drug absorption 91 
fall within predefined limits, comparable in vivo drug exposure is ensured. BE studies of 92 
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paediatric products are currently conducted in adults, with subsequent extrapolation to the 93 
target age group and a dose determination/confirmation study (Ricci, 2013). 94 
Bioequivalence studies may be exempted if in vitro dissolution testing can be used as a 95 
surrogate to adequately predict the in vivo drug performance (biowaivers), in accordance with 96 
regulatory guidelines. The BCS is a scientific tool which categorises drugs according to their 97 
(high or low) solubility and intestinal permeability (Amidon et al., 1995). This system has been 98 
adopted as a particularly useful tool for in vivo drug design and development, particularly in 99 
terms of regulatory standards. BCS-based biowaivers have become an important and cost-100 
saving tool in the development of new medicines, formulation bridging and generic drug 101 
approval. When combined with in vitro dissolution, BCS-based biowaivers take into account 102 
the three major factors that govern the rate and extent of oral drug absorption from IR dosage 103 
forms. An IR oral solid formulation (test product) is eligible for a BCS-based biowaiver if the 104 
drug satisfies solubility criterion (high solubility; BCS class I/III), and the dosage form is 105 
pharmaceutically equivalent to the reference product (EMA, 2010; FDA, 2017; ICH, 2018; 106 
WHO, 2006). BCS-based biowaiver criteria are detailed in regulatory guidance documents 107 
(EMA, 2010; FDA, 2017; ICH, 2018; WHO, 2006). It is required that at least 85 % of the 108 
labelled amount of drug substance should dissolve from the product within 15 min (BCS class 109 
III drugs) or 30 min (BCS class I drugs), in media across a pH range (pH 1.2, 4.5 and 6.8), 110 
using USP apparatus I (100 rpm) or II (50 rpm or 75 rpm (if appropriately justified)). FDA 111 
recommends a volume of dissolution media of 500 mL or less (900 mL can be used if 112 
appropriately justified); a volume of 900 mL or less is recommended in guidance from the 113 
EMA, WHO and in the ICH harmonised draft guideline. The time frame criterion for BCS class 114 
I drugs, is subdivided into very rapidly and rapidly dissolving products (time limits for reaching 115 
85% drug dissolved of 15 and 30 min, respectively) and similarity testing (i.e. f2) is required 116 
for rapidly dissolving products. There are no equivalent guidance documents for paediatric 117 
7 
 
products, and the relevance of the defined criteria in this population is unknown. Overall, the 118 
BCS-biowaiver approach has three main requirements: BCS classification, dissolution 119 
performance and risk assessment; this risk assessment is used to evaluate the benefits over the 120 
risks before a BCS-biowaiver is granted. These requirements would need to be addressed when 121 
considering a BCS-based biowaiver for paediatrics. 122 
Currently, biowaiver decisions are based on the drug properties, related to the risk of 123 
bioinequivalence in the adult population (based on e.g. physiological parameters and prior 124 
experience). However, a BCS-biowaiver approach for paediatric products would be beneficial 125 
towards producing age-appropriate medicines, whilst minimising/eliminating scientific 126 
regulatory risks associated with bioinequivalence in paediatrics. Potentially this could be 127 
explored if both the reference (e.g. adult formulation or enabling paediatric formulation) and 128 
test formulations are pharmaceutical equivalents exhibiting rapid and similar dissolution 129 
profiles.  130 
The use of the BCS in paediatrics is limited due to several biopharmaceutical particularities 131 
regarding paediatric physiology and PK parameters, therefore BCS-based biowaivers are not 132 
feasible for this population (Batchelor, 2014; Batchelor et al., 2016). These particularities 133 
include GI pH and volumes, which can influence drug solubility and ionised fraction. 134 
Additionally, permeability changes occur as function of the relative size of the small intestine, 135 
weight gain and maturation of GI transporters (e.g. P-glycoprotein) (Elder et al., 2017; 136 
Guimarães et al., 2019). Thus, the role of BCS and biowaivers in paediatric medicine 137 
development is unclear (Purohit, 2012; Selen et al., 2010). Additionally, the fact that relative 138 
BA and BE studies for paediatric products are performed in adults creates a potential paradox, 139 
whereby a drug product would be eligible for a BCS biowaiver based on adult parameters but 140 
could fail to meet the high solubility threshold if the volumes were scaled down as appropriate 141 
for the paediatric population.  142 
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In this context, it is important to investigate the possible changes on the biopharmaceutical 143 
characteristics of the drug as a function of the different age groups. Age-related physiological 144 
and/or anatomical changes may be responsible for shifts in the BCS classification of a drug due 145 
to changes in its solubility and permeability classification (Gandhi et al., 2014). Recent studies 146 
have shown that a drug which exhibits a high dose/solubility ratio in adults (i.e. highly soluble 147 
drugs) might not show the same ratio in paediatric patients, and unfavourably shift into poorly 148 
soluble classification. Consequently, these drugs would not be eligible for BCS-based 149 
biowaivers in the pediatric populations (delMoral-Sanchez et al., 2019; Gandhi et al., 2014; 150 
Shawahna, 2016).  151 
The aims of this study were to assess the risk of extending the biowaiver criteria for IR 152 
formulations from adults to paediatrics, and to identify bioinequivalence risks when comparing 153 
the performance of different formulations in age-appropriate BCS-conditions. The biowaiver 154 
decision was then discussed not only in terms of the formal requirements set out in existing 155 
guidance, but also in the context of the risks associated with an incorrect biowaiver decision. 156 
Drugs were selected based on the identified risk of shifting into poorly soluble classification in 157 
the different paediatric age groups and, consequently, not being eligible for a BCS-based 158 
biowaiver. Amoxicillin, amlodipine and prednisolone were selected as the model compounds. 159 
 160 
2. Materials and methods 161 
2.1 Materials  162 
Sodium hydroxide, 37 % hydrochloric acid, sodium chloride, glacial acetic acid, potassium 163 
dihydrogen phosphate, sodium acetate trihydrate and sodium phosphate anhydrous were 164 
purchased from Fisher Scientific (UK). Water was ultra-pure (Milli-Q) laboratory grade. RC 165 
membrane filters (0.45 µm) were from Cronus® (UK). Amoxicillin trihydrate (98 %) was 166 
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purchased from VWR (UK). Prednisolone (99 %) and amlodipine besylate (pharmaceutical 167 
secondary standard) were obtained from Sigma-Aldrich (UK). Details of the formulations used 168 
are presented in Table 1.  169 
 170 
Table 1 here 171 
 172 
2.2 Methods 173 
2.2.1 Drug and dose selection 174 
Amoxicillin (trihydrate), prednisolone and amlodipine (besylate) were selected as the model 175 
compounds. They are included in the Model List of Essential Medicines for Children, with two 176 
dose strengths specified for each drug (WHO, 2017). Two doses (a ‘low’ dose for paediatrics 177 
and a ‘high’ dose for adults) were selected for this study; these were: 250 and 500 mg for 178 
amoxicillin, 5 and 25 mg for prednisolone and 5 and 10 mg for amlodipine.  179 
The BCS allows the classification of drugs as highly soluble when the highest drug dose (or 180 
dose unit, D0) is soluble in 250 mL of an aqueous liquid, at a relevant physiological pH range 181 
of 1.2 – 6.8 (Amidon et al., 1995). According to this criterion, the three drugs (all doses used 182 
in this study) selected are classified as highly soluble drugs (Shohin et al., 2010; Thambavita 183 
et al., 2017; Vogt et al., 2007). The key factors that define drug dose unit (i.e. highest dose 184 
strength, initial gastric volume available (V0) and drug solubility) have been shown to vary 185 
amongst the different populations (Abdel-Rahman et al., 2012; Gandhi et al., 2014; Shawahna, 186 
2016). The paediatric D0 of these drugs were estimated across the different paediatric age 187 
groups (average age in each subpopulation was used for the calculations; Table 2), using 188 





 𝑉0 × Drug solubility
 (Eq. 1) 190 
where, aqueous drug solubility data was obtained from the literature (Wishart et al., 2007), and 191 
the initial gastric volumes for the paediatric subgroups were determined using Equation 2: 192 
𝑉0  =
Weight (kg) 𝑥 0.56 (mL/kg) 
37.1 (mL)
𝑥 250 mL (Eq. 2) 193 
where, 0.56 mL/kg and 37.1 mL are estimates of fasted gastric fluids volumes in paediatrics 194 
(Crawford et al., 1990) and adults (Goetze et al., 2009), respectively, and 250 mL is the 195 
reference volume used in the BCS (EMA, 2010; FDA, 2017; WHO, 2006). 196 
All drugs were shown to change D0 (Table 2) and consequently BCS class, with a shift from 197 
high drug solubility classification in adults to low drug solubility classification (given by D0 > 198 
1 (Batchelor, 2014)) in certain paediatric age groups. The BCS‐based biowaiver status claimed 199 
in adults may therefore not be safely extended to the paediatric population. Therefore, these 200 
drugs were selected as the model compounds for this study. 201 
 202 
Table 2 here 203 
 204 
 205 
2.2.2 In vitro dissolution studies 206 
In vitro dissolution studies were conducted with USP II apparatus or mini-paddle apparatus 207 
(Agilent 708-DS Dissolution apparatus; Agilent, USA). For the mini-paddle setup, TruAlign 208 
200 mL vessels and electropolished stainless steel mini-paddles were used (Agilent, USA). 209 
Experiments were conducted at 37 ± 0.5oC in three media; simulated gastric fluid sine pepsin 210 
(SGFsp) pH 1.2, acetate buffer pH 4.5 and phosphate buffer pH 6.8 (USP, 2007). Three 211 
different setups were developed for the assessment of formulation performance and 212 
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equivalence, in dissolution conditions representative of both adults and paediatric populations 213 
(Figure 1). Setup 1 was conducted in USP II apparatus, using 900 mL of dissolution media 214 
(maximum volume recommended in regulatory guidance documents) and an agitation of 50 215 
rpm (prednisolone and amlodipine) or 75 rpm (amoxicillin) (setup 1, ‘typical’ BCS-based 216 
biowaiver conditions). Setup 2 was conducted in USP II apparatus, using 250 mL of media and 217 
an agitation rate of 50 rpm (prednisolone and amlodipine) or 75 rpm (amoxicillin) (setup 2, 218 
derived from BE study protocols that prescribe administration of a drug product to fasting 219 
human volunteers with a glass of water of 250 mL). Setup 3 was conducted in mini-paddle 220 
apparatus, using 50 mL of dissolution media and an agitation rate of 125 rpm (prednisolone 221 
and amlodipine) or 187.5 rpm (amoxicillin) (setup 3, where a 50 mL volume representative of 222 
the paediatric population was used). The agitation rate for setup 3 in the mini-paddle apparatus 223 
(125 or 187.5 rpm) was set based on the speed factor of 2.5 between paddle and mini-paddle 224 
hydrodynamics [i.e. Agitation rate mini-paddle = 2.5 * agitation rate paddle] to reflect the 225 
agitation rate used in the USP II apparatus (50 or 75 rpm, respectively) (Scheubel et al., 2010). 226 
Other requirements for granting the biowaiver status (i.e. pH range for testing and time frame 227 
limits for rapid dissolution of the formulations) were maintained for all setups, as per current 228 
regulations. 229 
For amoxicillin capsules, slow dissolution was observed when testing at 50 rpm in media of 230 
pH 4.5 and 6.8. To explore the dissolution performance of the drug products and investigate if 231 
there were experimental issues of coning, dissolution tests were performed with Amoxil® 250 232 
and 500 mg capsules (reference product), in media of pH 4.5 and 6.8 at three agitation rate 233 
conditions; 50, 75 and 100 rpm. Two volumes were tested: 900 mL (setup 1) and 250 mL (setup 234 
2).  235 
Experiments were conducted for 60 min or 120 min, depending on whether complete 236 
dissolution was reached within 60 min. For amoxicillin testing, capsules were put in sinkers 237 
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(Quality Lab Accessories LCC, USA). Sample collection took place at 5, 10, 15, 20, 30, 45, 238 
60, 75, 90 and 120 min. 2 mL samples were withdrawn (with volume replacement) using a 2 239 
mL glass syringe (Fortuna Optima® fitted with a stainless tubing) through a cannula (Quality 240 
Lab Accessories LCC, USA). Each sample was filtered with a RC filter (0.45 µm), and 241 
appropriately diluted prior to quantitative analysis. All experiments were performed in 242 
triplicate. Samples were analysed at 272 (amoxicillin), 246 (prednisolone) and 239 243 
(amlodipine) nm, using an UV spectrophotometer (Thermo Scientific Helios Gamma UV-Vis 244 
Spectrophotometer, Thermo Fisher Scientific, UK) equipped with a cuvette. 245 
Drug quantification was performed based on calibration curves prepared in the corresponding 246 
media for each experiment. Freshly prepared standard solutions (concentration range: 5 – 120 247 
μg/mL (amoxicillin) or 2 – 30 μg/mL (prednisolone and amlodipine)) were prepared by 248 
appropriate dilution of a 1000 μg/mL stock solution of the analytical standard in water 249 
(amoxicillin) or methanol (prednisolone and amlodipine). The interfering effect of formulation 250 
excipients on the maximum absorption of the compounds was deemed insignificant, after 251 
scanning and comparing the spectrum of each stock solution with the spectrum of a solution of 252 
same concentration of the dissolved dosage forms in water (amoxicillin) or methanol 253 
(prednisolone or amlodipine) (data not shown). Results were expressed as mean percentage 254 
(%) drug dissolved ± S.D., at the given sampling time. 255 
 256 
Figure 1 here 257 
 258 
2.2.3 Treatment of dissolution data 259 
To qualify for a BCS-based biowaiver, both the test product and reference should display a 260 
mean % drug dissolved above 85 % within 15 or 30 min, and similar in vitro dissolution 261 
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characteristics, under all the defined conditions (i.e. agitation rate, pH range). When > 85% of 262 
the label amount of drug was dissolved in 15 min (for both test and reference products), the 263 
dissolution profiles were considered similar. If this was not the case, the similarity factor f2 264 
was estimated for comparison of dissolution profiles, by using the following equation (Eq. 3) 265 
(Shah et al., 1998): 266 





) (Eq. 3) 267 
where, 𝑛 is the number of time points, 𝑅(𝑡) is the mean percent of reference drug dissolved at 268 
time t after starting the study; and 𝑇(𝑡) is the mean percent of test drug dissolved at time 𝑡.  269 
DDsolver® software (an Add-In for Excel, Microsoft®) was used to calculate the similarity 270 
factor f2. The coefficient of variation was less than 20% at early time points and less than 10% 271 
at other time points, allowing the use of mean values for the calculation of the similarity factor; 272 
only one measurement was considered after 85% dissolution of each product (FDA, 2017). 273 
Two dissolution profiles were considered similar when the f2 value was ≥ 50 (Shah et al., 1998).   274 
 275 
3. Results and discussion  276 
3.1 Amoxicillin 277 
Amoxicillin can be classified as a BCS class I drug, for doses under 875 mg, according to drug 278 
solubility and permeability studies (Thambavita et al., 2017). According to regulations for 279 
BCS-based biowaivers, dissolution studies should be performed with USP II paddle apparatus 280 
at 50 rpm. Amoxicillin capsules had a slow and incomplete dissolution when dissolution testing 281 
was performed at this agitation rate in media of pH 4.5 and 6.8. At an agitation rate of 75 rpm 282 
and 100 rpm, dissolution of amoxicillin from the Amoxil® capsules (reference product; 250 mg 283 
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and 500 mg) was rapid and reached completion, with low variability between replicates. These 284 
results revealed that at lower agitation rate (50 rpm) coning effect was taking place (Figure 2). 285 
Therefore, the dissolution tests for the amoxicillin capsules were performed at 75 rpm (setup 1 286 
and 2) and 187.5 rpm (setup 3).  287 
 288 
Figure 2 here 289 
 290 
Dissolution of amoxicillin from the formulations tested (reference: Amoxil®; test: Teva® and 291 
Kent®) is presented in Figure 3 and f2 similarity factors estimated for comparison of the 292 
dissolution profiles in Table 3.  293 
For the 250 mg amoxicillin capsules, under setup 1 conditions at pH 1.2, more than 85% of 294 
amoxicillin was dissolved from the tested formulations within 15 min. In the acetate (pH 4.5) 295 
and phosphate (pH 6.8) buffers, dissolution of all the tested products was not rapid (% drug 296 
dissolved within 30 min was less than 85%). Dissolution of amoxicillin was complete within 297 
15 min in pH 1.2 media, 90 min in pH 4.5 media and 45 min in pH 6.8 media, and the 298 
dissolution profiles of the tested products (Teva® and Kent®) were similar to the dissolution 299 
profile of the reference product (Amoxil®) (f2 ≥ 50; Table 3). Consequently, the products would 300 
not qualify for biowaiver status. These results are in agreement with dissolution studies recently 301 
conducted based on USP methodologies and BCS-based biowaiver dissolution studies, which 302 
have showed high failure rates for amoxicillin products (Löbenberg et al., 2012; Reddy et al., 303 
2014; Stuart et al., 2014). The discrepant dissolution profiles are likely caused by poor 304 
manufacturing techniques or variation in the API particle size, and thus with appropriate 305 
content uniformity assays in addition to in vitro drug dissolution testing, this risk should be 306 
easily identified. Under setup 2 conditions, more than 85% of the labelled amount of 307 
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amoxicillin was dissolved in less than 15 min at pH 1.2, and under 30 min at pH 4.5 and 6.8 308 
for all products tested. Complete dissolution was achieved within 20 min in pH 1.2 media, and 309 
45 min in pH 4.5 and 6.8 media. Similarity comparison of the Teva® and Kent® products with 310 
the reference product showed that biowaiver status would be granted (pH 1.2: all products 311 
rapidly dissolved; pH 4.5: f2 = 60.6 (Amoxil
®-Kent®) and 62.8 (Amoxil®-Teva®); pH 6.8: f2 = 312 
73.1 (Amoxil®-Kent®) and 61.0 (Amoxil®-Teva®)). Since in vitro equivalence was shown 313 
between Amoxil® and the test products, the amoxicillin Teva® and Kent® capsules would be 314 
assumed as therapeutically equivalent to the reference product, under these testing conditions. 315 
With setup 3 conditions, the criterion for rapid dissolution was not met within the pH range 316 
tested. Dissolution was complete at pH 1.2 and 6.8 (within 15 and 75 min, respectively), but 317 
not at pH 4.5. Therefore, even though the products were shown to be similar (f2 ≥ 50; Table 3), 318 
they would not qualify for biowaiver status. The different results obtained with setups 1 and 3 319 
in comparison to setup 2 testing conditions may be related to the dissolution setup. When using 320 
a dissolution volume of 250 mL in USP II dissolution (setup 2), the paddles are very close to 321 
the medium surface, which not only requires careful sampling as it may lead to result variability 322 
but also shows that the different hydrodynamics impact drug dissolution, ultimately affecting 323 
the outcome of the product qualification for a BCS-based biowaiver.  324 
For the 500 mg capsules, the amoxicillin products would not qualify for a BCS-biowaiver under 325 
any of the setup conditions tested. Even though similarity was shown between the test and 326 
reference products (f2 ≥ 50; Table 3), the criterion for rapid dissolution was not met in any of 327 
the setups tested (setup 1 to 3; pH 1.2: all products rapidly dissolved; pH 4.5: % drug dissolved 328 
within 30 min was less than 85%; pH 6.8: drug dissolved within 30 min was less than 85% 329 
under setup 2 and 3 conditions). Under setup 1 conditions, complete dissolution was achieved 330 
in all media pH (100% drug dissolved reached within 15, 90 and 45 min at pH 1.2, 4.5 and 6.8, 331 
respectively). Under setup 2 conditions, complete dissolution was achieved in pH 1.2 and 6.8 332 
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media within 10 and 90 min, respectively, but not in pH 4.5 media. Under setup 3 conditions, 333 
complete dissolution was only achieved in pH 1.2 media, at pH 4.5 and 6.8 the maximum % 334 
dissolved within 2 h was 60 and 80%, respectively. These results show a clear impact of the 335 
pH-drug solubility profile on drug dissolution behaviour. Amoxicillin is an amphoteric 336 
compound (Thambavita et al., 2017); in acidic pH it is protonated, in a pH typical of the upper 337 
small intestine it exists primarily as a zwitterion, and in the distal small intestine (pH 6.5) it 338 
will exist both as zwitterion and as deprotonated acid. It has been shown to exhibit a pH-339 
dependent, U-shaped solubility curve (drug solubility in buffers of pH 1.2, 4.5, and 6.8 was 340 
7.7, 3.6 and 5.4 mg/mL, respectively) (Thambavita et al., 2017). Accordingly, drug dissolution 341 
rate was higher at pH 1.2, which can be correlated with the higher drug solubility in acidic 342 
conditions due to an increase in the ionisation % of the drug. For the 250 mg products (setup 343 
3) and 500 mg products (all setups), sink conditions were not achieved during the dissolution 344 
studies (i.e. having a volume of medium at least three times above the volume required to form 345 
a saturated drug solution (Gibaldi and Feldman, 1967)). Sink conditions are critical to ensure 346 
that reproducible dissolution occurs; moreover, under non-sink conditions in vitro results may 347 
have little relationship with in vivo observations (Gibaldi and Feldman, 1967). 348 
Overall, the 250 mg amoxicillin products tested would fail to meet the in vitro dissolution 349 
criterion associated with the BCS-based biowaiver requirements in setups 1 and 3 conditions 350 
and would pass in setup 2 conditions. As previously mentioned, the difference in outcomes 351 
between setup 2 conditions and the other setups is likely related to the impact of 352 
hydrodynamics. For the 500 mg amoxicillin capsules, the tested products would fail to meet 353 
BCS-based biowaiver requirements in all the setup scenarios tested.  354 
Amoxicillin is a broad spectrum, beta-lactam antibiotic, mainly used in an ambulatory setting 355 
for infections of mild-to-moderate severity (Eyer, 2002; Thambavita et al., 2017). Since it has 356 
a wide therapeutic range (Doogue and Polasek, 2011), the possibility of life-threatening toxic 357 
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reactions with supra-therapeutic doses of amoxicillin is very low. On the other hand, the risk 358 
associated with subtherapeutic blood levels is unknown; a false-positive biowaiver decision, 359 
particularly if the products are severely below the accepted level of bioequivalence, could 360 
possibly lead to prolongation of illness, and even to the development of resistance if the drug 361 
content significantly differs from the labelled amount (Gustafsson et al., 2001). In this study, 362 
the products are not rapidly dissolved in pH 4.5 in setup 1 conditions and a biowaiver for an 363 
adult formulation would not be granted. Furthermore, since the paediatric population undergoes 364 
developmental changes (e.g. gastric pH and emptying, intestinal transit time, membrane 365 
permeability, body water, distribution and metabolism), which may lead to a significant 366 
alteration of the plasma concentration profile and of key bioequivalence parameters (e.g. Cmax 367 
and AUC), bioinequivalence risks might be increased in this population (Batchelor et al., 2014; 368 
Guimarães et al., 2019). Consequently, a BCS-based biowaiver status of these products could 369 
also not be applied for administration in paediatrics. 370 
 371 
Figure 3 and Table 3 here 372 
 373 
3.2 Prednisolone  374 
Dissolution profiles of prednisolone from the products tested (reference: Pevanti®; test: 375 
Actavis®) are presented in Figure 4 and f2 similarity factor results are shown in Table 3. 376 
Results of dissolution studies of the 5 mg prednisolone tablets revealed that more than 85% of 377 
the labelled amount of prednisolone was dissolved in less than 15 min, under all the setup 378 
scenarios tested. Under setup 1 and 2 conditions, complete dissolution was achieved in pH 1.2 379 
and 6.8 media within 15 min and in pH 4.5 media within 20 min. Under setup 3 conditions, 380 
complete dissolution was achieved in all pH within 30 min. Due to having met very rapidly 381 
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dissolution criterion, in vitro equivalence was shown between prednisolone Actavis® and 382 
Pevanti® tablets, in all the setup testing conditions performed. The test product can be assumed 383 
as therapeutically equivalent to the reference, with no need for in vivo bioequivalence studies.  384 
For the 25 mg tablets, under setup 1 conditions, complete dissolution was achieved in pH 1.2 385 
media within 20 min and in pH 4.5 and 6.8 media within 45 min. Comparison of the dissolution 386 
studies of the test (Actavis®) and the reference (Pevanti®) products showed that following BCS-387 
based dissolution testing conditions, biowaiver status would be granted (rapidly dissolved 388 
products; f2 ≥ 50; Table 3). Under setups 2 and 3 dissolution conditions, the products would 389 
not qualify for biowaiver status. Under setup 2 dissolution conditions, although more than 85% 390 
of the labelled drug amount in the dosage form was dissolved in less than 30 min, f2 analysis 391 
revealed that the test and reference products were not similar (pH 4.5 and 6.8: f2 (Actavis
®-392 
Pevanti®) = 47.5 and 38.0, respectively). Under these conditions, complete dissolution was 393 
achieved within 20 min in pH 1.2 media and within 45 min in pH 4.5 and 6.8 media. When 394 
testing under setup 3 dissolution conditions (mini-paddle apparatus, 125 rpm, 50 mL), the test 395 
product would not qualify for BCS-based biowaiver status since rapid dissolution criterion (> 396 
85% dissolved in less than 30 min) was not met, even though f2 analysis revealed similarity 397 
between test and reference products (f2 > 50; Table 3). Sink conditions in dissolution testing of 398 
both products were not achieved with this dose (25 mg) in 50 mL, as revealed by the lower 399 
dissolution (maximum % drug dissolved at 2 h was 89.0 and 85.5%, for Pevanti® and Actavis®, 400 
respectively).  401 
Overall, the 5 mg prednisolone products tested would meet the in vitro dissolution criterion 402 
associated with the BCS-based biowaiver requirements, in all the setup conditions tested. For 403 
the 25 mg tablets, the products would meet BCS-based biowaiver requirements in setup 1 404 
conditions, but not under setup 2 and 3 conditions tested.  405 
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According to drug solubility and permeability studies, prednisolone can be classified as a BCS 406 
Class I drug (Vogt et al., 2007). When calculating the D0 for the 25 mg tablets, prednisolone 407 
was shown to change solubility class to low solubility in younger age groups (Table 2). This is 408 
reflected in the results obtained when testing the 25 mg formulations, under setup 2 and 3 409 
conditions. In this context, formulation bridging into paediatrics could result in a false 410 
biowaiver decision (i.e. wrongly declaring the test formulation bioequivalent to the reference 411 
formulation in the paediatric population). This could affect the in vivo drug behaviour, resulting 412 
in changes in the AUC and/or Cmax of the drug. If resulting in a lower AUC, the products might 413 
be clinically less effective in paediatric patients and/or potentially lead to serious clinical 414 
consequences when acute treatment is required for severe, life-threatening diseases. In this 415 
case, as prednisolone is a prescription-only drug, therapy should be periodically reviewed, and 416 
a dose adjustment/ substitution would be required. If the drug became supra-bioavailable (i.e. 417 
resulted in a higher AUC than intended), the risk of toxicity and/or side effects would increase 418 
(Robinson et al., 2016; Vogt et al., 2007). If bioinequivalence was caused by a difference in 419 
Cmax, clinical implications could be expected since prednisolone IR tablets are usually used in 420 
chronic therapeutic regimes (Paediatric Formulary Committee, 2017). 421 
 422 
Figure 4 here 423 
 424 
3.3 Amlodipine  425 
Dissolution of amlodipine from the products tested (reference: Istin®; test: Sandoz® and Teva®) 426 
and f2 similarity factor results are presented in Figure 5 and Table 3, respectively. 427 
For the 5 mg tablets, under setup 1 testing conditions, more than 85% of amlodipine was 428 
dissolved within 15 min, in pH 1.2 and pH 4.5 media. At pH 6.8, although f2 analysis revealed 429 
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similarity between the dissolution profiles of the tested products in relation to the reference, 430 
the criterion for rapid dissolution was not met (i.e. 85% of drug dissolution within 30 min). 431 
Therefore, the products would not qualify for biowaiver status. Complete dissolution was 432 
achieved in pH 1.2 and 4.5 media within 10 min and in pH 6.8 media within 60 min. The lower 433 
dissolution rate observed at pH 6.8 could be explained by drug characteristics; since amlodipine 434 
is a weak base (pKa 8.7 (Van Zwieten, 1994)), it is affected by changes in pH and exhibits pH-435 
dependent solubility (Shohin et al., 2010; Van Zwieten, 1994). Under setups 2 and 3 conditions, 436 
more than 85% of the labelled amount of amlodipine was dissolved in less than 15 min. Having 437 
met the very rapidly dissolution criterion, in vitro equivalence was shown between the test 438 
products and the reference, and the products would qualify for BCS-biowaiver status.  439 
For the 10 mg tablets, under setup 1 (BCS-based dissolution testing) and setup 2 conditions, % 440 
drug dissolved was higher than 85% under 15 min at pH 1.2 and 4.5, and under 30 min at pH 441 
6.8, for all products tested. Under both setup conditions, complete dissolution was achieved 442 
within 15 min in media of pH 1.2 and 4.5, and within 45 (setup 1) or 60 (setup 2) min at pH 443 
6.8. Similarity comparison of the Teva® and Istin® (reference) tablets showed that biowaiver 444 
status would be granted for the test product (pH 1.2 and 4.5: rapidly dissolved products; pH 445 
6.8: f2 (Istin
®-Teva®) = 50.7 and 64.3 for setups 1 and 2, respectively). On the contrary, 446 
comparison of Sandoz® and reference (Istin®) tablets showed that biowaiver status would not 447 
be granted for the test product (pH 1.2 and 4.5: rapidly dissolved products; pH 6.8: f2 (Istin
®-448 
Sandoz®) = 48.4 and 40.0 for setups 1 and 2, respectively). In the case of the formulations 449 
tested (10 mg tablets), the differences observed in the dissolution of amlodipine could be 450 
attributed to the excipients used and/or manufacturing methods. Under setup 3 conditions 451 
(mini-paddle, 50 mL, 125 rpm), complete dissolution was achieved in pH 1.2 and 4.5 media 452 
within 10 min and in pH 6.8 media within 45 min. % drug dissolved was higher than 85% 453 
under 15 min at pH 1.2 and 4.5, and under 30 min at pH 6.8 for all products tested, and f2 454 
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analysis revealed similarity between all products (pH 1.2 and 4.5: rapidly dissolved products; 455 
pH 6.8:  f2 (Istin
®-Sandoz®) = 81.4, f2 (Istin
®-Teva® = 52.7)). Therefore, biowaiver status would 456 
be granted for all products. 457 
Overall, results revealed that the 5 mg amlodipine tablets tested would fail to meet the in vitro 458 
dissolution criterion associated with the BCS-based biowaiver requirements in setup 1 459 
conditions and would pass in setup 2 and 3 conditions. Regarding the 10 mg amlodipine tablets, 460 
the Istin® and Teva® products would qualify for a BCS-based biowaiver status under all setup 461 
scenarios tested, while the Sandoz® products would not qualify for a biowaiver status in setup 462 
1 and 2 conditions but would qualify in setup 3 conditions.  463 
Regarding evaluating patient risks associated with bioinequivalence, a false-positive biowaiver 464 
decision for amlodipine IR dosage forms could result in subtherapeutic plasma concentrations 465 
(which may lead to a therapeutic failure) or to concentrations above the recommended upper 466 
therapeutic concentrations (which may result in adverse drug reactions). Amlodipine is 467 
indicated for hypertension (Flynn et al., 2000; Murdoch and Heel, 1991; Van Zwieten, 1994). 468 
In general, drug dose is individualized depending on the severity of disease, tolerance and 469 
responsiveness of the patient to the drug (Murdoch and Heel, 1991). In these situations, it is 470 
necessary to ensure BE of the product, so that the therapeutic outcome from treatment with test 471 
products could be well predicted during the management of pharmacological indications. As 472 
far as supra-therapeutic drug levels, mild to moderate side effects have been reported (Murdoch 473 
and Heel, 1991). Patient risks associated with the subtherapeutic levels pose more serious 474 
consequences because of therapeutic insufficiency; these can be exacerbated in very young age 475 
groups as a recent study has shown that amlodipine dosing has a significant inverse relationship 476 
with patient age, with the youngest children requiring the highest doses of amlodipine (Flynn 477 




Figure 5 here  480 
 481 
3.4 Risk assessment of extending BCS-based biowaiver criteria into paediatrics 482 
A summary of the results obtained in this study, and assessment of whether the biowaiver status 483 
as currently defined would be granted in each situation, is presented in Figure 6.  484 
Results revealed that only the 5 mg prednisolone and the 10 mg amlodipine tablets (Istin® and 485 
Teva® but not Sandoz®) would qualify for a biowaiver status, under all setup scenarios tested. 486 
In view of these results, it seems clear that extrapolation of the BCS-based biowaiver criteria 487 
into paediatrics is not straightforward and cannot be based on direct assumptions (i.e. simple 488 
scaling down).  489 
When analysing the risk of extending BCS-based biowaiver testing criteria into products for 490 
the paediatric population, it is important to consider the factors that would affect BCS-based 491 
biowaiver decisions and the relevance of the criteria within the paediatric population. BCS-492 
based biowaiver decisions are considered for highly soluble drugs, which are expected to 493 
exhibit fast dissolution rates. Currently, drugs are classified as highly soluble if the highest 494 
dose strength is soluble in at least 250 mL of aqueous liquid at a relevant physiological pH 495 
range of 1.2 – 6.8, however these aspects concern adult physiology. Age-related changes in 496 
anatomy and physiology will impact the classification of drug solubility and permeability 497 
properties within the different paediatric subpopulations. Several issues arise regarding drug 498 
solubility classification amongst the paediatric population, including the definition of the 499 
highest single dose, the initial gastric volume, and the luminal solubility of the drug. Moreover, 500 
with respect to drug permeability classification, drugs are classified as highly permeable when 501 
the extent of oral absorption (i.e. fraction of dose absorbed) is greater than 85% of the 502 
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administered dose. However, using adult permeability data for paediatric subjects is 503 
controversial and information regarding permeability in younger paediatric subgroups is still 504 
lacking, hindering the establishment of meaningful permeability criteria for this population. 505 
Similarly, a drug that exhibits a high dose/solubility ratio in adults (i.e. highly soluble drug) 506 
might not show the same ratio in paediatric patients, and unfavourably shift into poorly soluble 507 
classification. In this study, except for the case of prednisolone in a dose of 5 mg, the chosen 508 
model compounds selected would change from high drug solubility classification in adults to 509 
low drug solubility class in paediatric age groups (D0 > 1; Table 2). These drugs would not be 510 
eligible for BCS-based biowaiver status, as the solubility criterion was not met, even at the 511 
relevant paediatric doses tested. In this context, a p-BCS approach could provide a simplistic 512 
tool to help understand possible age-related physiological and/or anatomical changes in oral 513 
drug performance, and identify risks associated with a change in BCS class of a compound and 514 
eligibility for BCS-based biowaivers for paediatric products.  515 
Regarding testing methodology, dissolution testing with USP I/II apparatus is commonly used 516 
to assess the dissolution rate of drug products, and in the case of BCS-based biowaivers rapid 517 
dissolution is required across a pH range. The basis of this approach is that the dosage form is 518 
agitated at a fixed rate within a fixed media volume, representative of the GI environment. 519 
Some limitations associated with this apparatus have been reported, including the impossibility 520 
of using small testing volumes (Crist, 2009; Scheubel et al., 2010). This is of importance as the 521 
fluid volumes available in the GI tract of younger age groups are smaller than adults (Batchelor 522 
et al., 2014). In the present study, an adaptation of standard USP II apparatus to a mini-paddle 523 
apparatus was tested as an appropriate method to address the need for small volume testing. 524 
The mini-paddle apparatus is already commonly used when screening for critical quality 525 
attributes of rapid dissolving tablets, in cases where it is difficult to detect differences using 526 
standard working conditions (Crist, 2009). Regarding agitation rate criterion, rates of 50 and 527 
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100 rpm have been defined for paddle and basket apparatus, respectively (Batchelor et al., 528 
2013; FDA, 2017; Purohit, 2012). A direct extrapolation from the agitation rates set for the 529 
USP II apparatus (50 or 75 rpm) to the mini-paddle was made according to a speed factor, 530 
which allowed the maintenance of discriminatory conditions.  531 
The dissolution media volume was considered in this study and its effect on drug dissolution 532 
was evaluated by comparison of different setup conditions. Volume scaling down is a 533 
commonly used approach in paediatric biopharmaceutics to simulate the lower gastrointestinal 534 
volumes of the paediatric population in comparison to adults. Since currently there is no 535 
guidance on appropriate volumes to use in paediatric dissolution testing, a direct extrapolation 536 
from the adult value of 250 mL utilised in USP II dissolution was conducted for the mini-537 
paddle apparatus (50 mL; setup 3). An important factor in BCS-style bridging is that dissolution 538 
rate of paediatric medicines needs to be rapid to ensure adequate exposure in this population 539 
and guarantee that GI transit dictates drug absorption rather that drug dissolution. In this 540 
context, the 5 mg prednisolone and 10 mg amlodipine tablets (Istin® and Teva® but not 541 
Sandoz®) would be eligible for a BCS-based biowaiver; however, all the amoxicillin products 542 
(250 and 500 mg), the lowest dose amlodipine products and the highest dose products of 543 
prednisolone would fail to be classified as rapidly dissolved. In the case of the amlodipine 5 544 
mg tablets, the products would fail the criterion of rapid dissolution under setup 1 conditions 545 
(current requirements for BCS-based biowaivers) due to slow dissolution in pH 6.8 but would 546 
pass when the volume was scaled down (setups 2 and 3). In the case of the prednisolone 25 mg 547 
tablets, the products would meet the criterion of rapid dissolution under setup 1 conditions 548 
(current requirements for BCS-based biowaivers), but would fail when the volume was scaled 549 
down, likely due to the solubility of the drug.   550 
The time limits set to define rapid dissolution criteria might also affect the biowaiver status, as 551 
subsequent analysis of the dissolution profiles differs accordingly. For example, in the present 552 
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study it was shown that when the products did not meet the criteria for very rapidly or rapidly 553 
dissolving products, it was because both the test and reference products did not exhibit fast 554 
dissolution and not due to dissimilarity between profiles (except for the case of the Sandoz® 555 
amlodipine 10 mg tablets). This could indicate that the time frame for rapid drug dissolution 556 
should be further evaluated, and potentially refined when considering the paediatric population. 557 
A minimum of 50% of drug release within 15 min has been recently suggested to support a 558 
biowaiver decision for paediatric formulations (Abdel-Rahman et al., 2012). With this 559 
criterion, the formulations studied in mini-paddle setup would be considered as rapidly 560 
dissolved, except for the case of amoxicillin 500 mg capsules for which drug dissolution was 561 
shown to be limited by drug solubility. The scientific basis for such alterations regarding the 562 
most appropriate time frames for evaluating dissolution rates, would need to be further 563 
evaluated.  564 
Excipients have also been shown to affect the fraction of dose absorbed (e.g. by modulating 565 
disintegration, drug solubilisation or stabilizing a specific polymorphic form), and therefore 566 
might impact the drug dissolution characteristics (Batchelor et al., 2014). This impact may be 567 
more significant in very young paediatric groups, for whom certain excipients might affect GI 568 
absorption, even if they have been considered safe and acceptable for adults (Batchelor et al., 569 
2014; Walsh et al. 2014). 570 
Another point to consider is that tablets are commonly crushed and sometimes mixed with 571 
food/drinks prior to paediatric administration, which might affect drug solubilization and 572 
dissolution behaviour (Martir et al., 2020). These potential changes were not considered in this 573 
study as the aim was to study the extrapolation of the current protocol used for BCS-based 574 
biowaivers to paediatrics.  575 
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Overall, the risk of using the BCS adult classification in paediatric drug development lies in 576 
shifts in BCS classification of drugs due to growth and maturation of paediatric subpopulations. 577 
Results from this study reveal the need for the development and establishment of a p-BCS, as 578 
a simplistic tool to help understand possible changes in oral drug performance in the paediatric 579 
population. The development and establishment of a p-BCS could meaningfully impact the 580 
paediatric biopharmaceutical field and guide the production of age-appropriate medicines and 581 
facilitate formulation bridging. While such a tool remains to be developed, extrapolation of the 582 
adult BCS classification should be performed with care.  583 
 584 
Figure 6 here 585 
 586 
4. Conclusions 587 
The use of BCS-based biowaivers for paediatric products needs to be undertaken with caution 588 
due to differences in the drug D0 between adults and paediatrics.  589 
In this study, the risk of directly extrapolating BCS-based criteria into paediatrics was assessed. 590 
A dissolution setup potentially representative of the paediatric population in terms of the lower 591 
volumes required was tested (setup 3), with the criteria limits used in BCS-based biowaiver 592 
guidance being applied for product evaluation/risk assessment. It was shown that a simple 593 
scaling down of the dissolution testing volume stipulated on BCS‐based biowaiver dissolution 594 
criteria may not be adequate for paediatric products. Knowledge of the solubility classification 595 
of a drug across different age groups, would assist on assessing the development of a biowaiver 596 
as BE testing surrogate in the different age groups. Therefore, a consensus on a p-BCS needs 597 
to be reached and should address the heterogeneity of the paediatric population.  598 
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Overall, the establishment of a p-BCS would contribute to formulation bridging (e.g. surrogate 599 
the need for future clinical BE testing) and risk assessment decisions, thus promoting paediatric 600 
drug development. This would result in a smaller discrepancy between technologies available 601 
for the different age groups and provide better support for the development and testing of age-602 
appropriate medicines, ultimately leading to a minimisation of clinical trials and regulatory 603 
burden. 604 
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Table 1. Information of the formulations used in this study. 752 










250 mg (2398) 
500 mg (X54F) 
Magnesium stearate E572, 
gelatine, erythrosine E127, 
titanium dioxide E171, 
indigotine E132, iron oxide 
yellow E172 and shellac E904 
Teva® capsules 
Teva Pharmaceutical 







magnesium stearate, sunset 
yellow E110, carmosine E122, 
brilliant blue E133, Quinoline 












Magnesium stearate, maize 
starch, gelatine, erythrosine 
E127, quinoline Yellow E104, 










Potato starch, lactose, talc, 
gelatine and magnesium 
stearate 
Actavis® tablets 
Actavis Generics Ltd 
(UK) 
5 mg (4F46) 
25 mg (YK13) 
Lactose monohydrate, 
pregelatinized starch, sodium 
starch glycolate type A, iron 
oxide yellow E172, iron oxide 





Pfizer Ltd  
(UK) 
5 mg (2398) 
10 mg (X54F) 
Calcium hydrogen phosphate 
anhydrous, magnesium 
stearate, microcrystalline 
cellulose and sodium starch 
glycolate type A. 
Sandoz® tablets 







anhydrous calcium hydrogen 
phosphate, sodium starch 











calcium hydrogen phosphate, 
sodium starch glycolate and 
magnesium stearate. 
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Table 2. Dose unit in different age groups from early infancy through to adulthood. Paediatric 755 
reference volumes were calculated with the average weight of the age group* (Guimarães et 756 
al., 2019). Low and high drug solubility classification are denoted by red (D0 > 1) and black 757 











3 Years / 
V0 = 54 mL 
6 Years / 
V0 = 79.2 mL 
10 Years / 
V0 = 121 mL 
17 Years / 
V0 = 245 mL 
Adult / 





250 1.350 0.920 0.602 0.297 0.292 
500 2.699 1.841 1.205 0.595 0.583 
Prednisolone 0.223 
5 0.415 0.283 0.185 0.092 0.0897 




5 1.230 0.838 0.549 0.271 0.266 
10 2.459 1.677 1.098 0.542 0.531 
(D0 = dose unit; V0 = gastric volume available) 759 
*average weight: 3 years: 14.3kg; 6 years: 21kg; 10 years: 32kg; 17 years: 65kg 760 
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Table 3. f2 similarity factor values for the comparison of drug dissolution profiles from the test 763 
and the reference formulation (f2 ≥ 50 denotes similarity; red values: f2 < 50 denotes non 764 
similarity between profiles). (-) % drug dissolved > 85% within 15 min. 765 
f2 value 
Amoxicillin - 250 mg Amoxicillin - 500 mg 
pH 1.2 pH 4.5 pH 6.8 pH 1.2 pH 4.5 pH 6.8 
Setup 
1 
Amoxil® vs Kent® - 68.4 68.5 - 53.9 66.2 
Amoxil® vs Teva® - 78.2 74.0 - 56.6 85.1 
Setup 
2 
Amoxil® vs Kent® - 60.6 73.1 - 55.6 63.0 
Amoxil® vs Teva® - 62.8 61.0 - 63.9 62.3 
Setup 
3 
Amoxil® vs Kent® - 79.0 54.2 - 69.2 67.0 
Amoxil® vs Teva® - 51.2 51.1 - 63.3 62.4 
 
Prednisolone - 5 mg Prednisolone - 25 mg 
pH 1.2 pH 4.5 pH 6.8 pH 1.2 pH 4.5 pH 6.8 
Setup 
1 
Pevanti® vs Actavis® - - - - 72.4 54.0 
Setup 
2 
Pevanti® vs Actavis® - - - - 47.5 38.0 
Setup 
3 
Pevanti® vs Actavis® - - - 83.8 73.1 81.6 
 
Amlodipine - 5 mg Amlodipine - 10 mg 
pH 1.2 pH 4.5 pH 6.8 pH 1.2 pH 4.5 pH 6.8 
Setup 
1 
Istin® vs Sandoz® - - 65.9 - - 48.4 
Istin® vs Teva® - - 58.3 - - 50.7 
Setup 
2 
Istin® vs Sandoz® - - - - - 40.0 
Istin® vs Teva® - - - - - 64.3 
Setup 
3 
Istin® vs Sandoz® - - - - - 81.4 
Istin® vs Teva® - - - - - 52.7 
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Figure Captions 767 
Figure 1. Schematic representation of the different dissolution setups tested: (1) Setup 1: 900 mL, USP 768 
II apparatus; (2) Setup 2: 250 mL, USP II apparatus; (3) Setup 3: 50 mL, mini-paddle apparatus. 769 
 770 
Figure 1. Mean % amoxicillin dissolved (± S.D.) from Amoxil® capsules 250 mg (full lines) and 500 771 
mg (dashed lines), in acetate buffer pH 4.5 (top) and phosphate buffer pH 6.8 (bottom), under two 772 
testing scenarios: setup 1 (USP II apparatus, 900 mL) and setup 2 (USP II apparatus, 250 mL) (left and 773 
right panels, respectively). Three agitation rates were tested: 50 rpm (blue), 75 rpm (red) and 100 rpm 774 
(black). 775 
 776 
Figure 3. Mean % amoxicillin dissolved (± S.D.) from Amoxil®, amoxicillin Teva® and amoxicillin 777 
Kent® capsules 250 mg (left panels) and 500 mg (right panels), in SGFsp pH 1.2 (blue), acetate buffer 778 
pH 4.5 (green) and phosphate buffer pH 6.8 (red). Three setup scenarios were tested: (1) setup 1: 900 779 
mL, 75 rpm, USP II apparatus; (2) setup 2: 250 mL, 75 rpm, USP II apparatus; (3) setup 3: 50 mL, 780 
187.5 rpm, mini-paddle apparatus (from top to bottom). Dotted grey lines represent the limit for ‘very 781 
rapid dissolution’ classification (> 85% dissolved within 15 min). 782 
 783 
Figure 4. Mean % prednisolone dissolved (± S.D.) from Pevanti® and prednisolone Actavis® tablets 5 784 
mg (left panels) and 25mg (right panels), in SGFsp pH 1.2 (blue), acetate buffer pH 4.5 (green) and 785 
phosphate buffer pH 6.8 (red). Three setup scenarios were tested: (1) setup 1: 900 mL, 50 rpm, USP II 786 
apparatus; (2) setup 2: 250 mL, 50 rpm, USP II apparatus; (3) setup 3: 50 mL, 125 rpm, mini-paddle 787 
apparatus (from top to bottom). Dotted grey lines represent the limit for ‘very rapid dissolution’ 788 




Figure 5. Mean % amlodipine dissolved (± S.D.) from Istin®, amlodipine Sandoz® and amlodipine 791 
Teva® tablets 5 mg (left panels) and 10 mg (right panels), in SGFsp pH 1.2 (blue), acetate buffer pH 792 
4.5 (green) and phosphate buffer pH 6.8 (red) under three testing scenarios. Three setup scenarios were 793 
tested: (1) setup 1: 900 mL, 50 rpm, USP II apparatus; (2) setup 2: 250 mL, 50 rpm, USP II apparatus; 794 
(3) setup 3: 50 mL, 125 rpm, mini-paddle apparatus (from top to bottom). Dotted grey lines represent 795 
the limit for ‘very rapid dissolution’ classification (≥ 85% dissolved within 15 min). 796 
 797 
Figure 6. Risk assessment of extending the BCS-biowaiver from the adult to the paediatric population 798 
for IR formulations of 3 model compounds. Green and red colours denote pass and fail of the rapid 799 
dissolution criterion, respectively. (N/A: not applicable; (+): meet the criterion; (-): fail the criterion; 800 
+/-: the Istin ® and Teva® products meet the criterion while the Sandoz® product does not). 801 
 802 
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Figure 2 810 
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Figure 3 814 
 815 
 816 
  817 
40 
 
Figure 4 818 
 819 
 820 
  821 
41 
 
Figure 5 822 
 823 
 824 
  825 
42 
 
Figure 6 826 
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